Phase II Trial of Gemcitabine Plus Cisplatin in Patients With Metastatic Urothelial Cancer

Donald Kaufman; Derek Raghavan; Michael Carducci; Ellis Glenn Levine; Barbara Murphy; Joseph Aisner; Timothy Kuzel; Steven Nicol; William Oh; Walter Stadler

doi:10.1200/JCO.2000.18.9.1921

Back

Phase II Trial of Gemcitabine Plus Cisplatin in Patients With Metastatic Urothelial Cancer

Journal article

Peer reviewed

Phase II Trial of Gemcitabine Plus Cisplatin in Patients With Metastatic Urothelial Cancer

Donald Kaufman, Derek Raghavan, Michael Carducci, Ellis Glenn Levine, Barbara Murphy, Joseph Aisner, Timothy Kuzel, Steven Nicol, William Oh and Walter Stadler

Journal of clinical oncology, Vol.18(9), pp.1921-1927

05/09/2000

DOI: https://doi.org/10.1200/JCO.2000.18.9.1921

PMID: 10784633

Abstract

PURPOSE: To assess the activity and toxicity of the combination of gemcitabine and cisplatin in the treatment of chemotherapy-naive patients with metastatic urothelial cancer. PATIENTS AND METHODS: Forty-six patients with measurable stage IV carcinoma of the urothelium were enrolled onto this trial. Gemcitabine 1,000 mg/m2 was administered intravenously for 30 to 60 minutes on days 1, 8, and 15 of each 28-day cycle. Cisplatin was administered after gemcitabine on day 1 of each cycle. The first 11 patients received an initial cisplatin dose of 100 mg/m2. Due to the hematologic toxicity observed in several of these patients, the dose was reduced to 75 mg/m2 in the remaining 35 patients. Patients were treated with six cycles, unless disease progression or severe toxicity necessitated earlier discontinuation. RESULTS: Ten of the 46 patients achieved a complete response and nine showed a partial response. The overall response rate was 41%. The median time to treatment failure was 5.5 months. The median survival was 14.3 months, and the 1-year survival probability was 54%. Most of the toxicities were hematologic and, in general, easily manageable. CONCLUSION: Gemcitabine plus cisplatin is active in the treatment of metastatic urothelial cancer in chemotherapy-naive patients and has an acceptable clinical safety profile. Studies are under way to further define the place of gemcitabine in combination with other chemotherapeutic agents in the treatment of metastatic urothelial cancer.

Metrics

14 Record Views

181 Times Cited - Web of Science

See more details

Details

Title: Phase II Trial of Gemcitabine Plus Cisplatin in Patients With Metastatic Urothelial Cancer
Creators: Donald Kaufman - From the Massachusetts General Hospital and Dana-Farber Cancer InstituteBoston, MA; University of Southern California–Norris Comprehensive Cancer Center, Los Angeles, CA; Johns Hopkins University, Baltimore, MD; Roswell Park Cancer Institute, Buffalo, NY; Vanderbilt University School of Medicine, Nashville, TN; Cancer Institute of New Jersey, New Brunswick, NJ; University of Chicago and Northwestern University Medical School, Chicago, IL; and Eli Lilly and Company, Indianapolis, IN
Derek Raghavan - From the Massachusetts General Hospital and Dana-Farber Cancer InstituteBoston, MA; University of Southern California–Norris Comprehensive Cancer Center, Los Angeles, CA; Johns Hopkins University, Baltimore, MD; Roswell Park Cancer Institute, Buffalo, NY; Vanderbilt University School of Medicine, Nashville, TN; Cancer Institute of New Jersey, New Brunswick, NJ; University of Chicago and Northwestern University Medical School, Chicago, IL; and Eli Lilly and Company, Indianapolis, IN
Michael Carducci - From the Massachusetts General Hospital and Dana-Farber Cancer InstituteBoston, MA; University of Southern California–Norris Comprehensive Cancer Center, Los Angeles, CA; Johns Hopkins University, Baltimore, MD; Roswell Park Cancer Institute, Buffalo, NY; Vanderbilt University School of Medicine, Nashville, TN; Cancer Institute of New Jersey, New Brunswick, NJ; University of Chicago and Northwestern University Medical School, Chicago, IL; and Eli Lilly and Company, Indianapolis, IN
Ellis Glenn Levine - From the Massachusetts General Hospital and Dana-Farber Cancer InstituteBoston, MA; University of Southern California–Norris Comprehensive Cancer Center, Los Angeles, CA; Johns Hopkins University, Baltimore, MD; Roswell Park Cancer Institute, Buffalo, NY; Vanderbilt University School of Medicine, Nashville, TN; Cancer Institute of New Jersey, New Brunswick, NJ; University of Chicago and Northwestern University Medical School, Chicago, IL; and Eli Lilly and Company, Indianapolis, IN
Barbara Murphy - From the Massachusetts General Hospital and Dana-Farber Cancer InstituteBoston, MA; University of Southern California–Norris Comprehensive Cancer Center, Los Angeles, CA; Johns Hopkins University, Baltimore, MD; Roswell Park Cancer Institute, Buffalo, NY; Vanderbilt University School of Medicine, Nashville, TN; Cancer Institute of New Jersey, New Brunswick, NJ; University of Chicago and Northwestern University Medical School, Chicago, IL; and Eli Lilly and Company, Indianapolis, IN
Joseph Aisner - From the Massachusetts General Hospital and Dana-Farber Cancer InstituteBoston, MA; University of Southern California–Norris Comprehensive Cancer Center, Los Angeles, CA; Johns Hopkins University, Baltimore, MD; Roswell Park Cancer Institute, Buffalo, NY; Vanderbilt University School of Medicine, Nashville, TN; Cancer Institute of New Jersey, New Brunswick, NJ; University of Chicago and Northwestern University Medical School, Chicago, IL; and Eli Lilly and Company, Indianapolis, IN
Timothy Kuzel - From the Massachusetts General Hospital and Dana-Farber Cancer InstituteBoston, MA; University of Southern California–Norris Comprehensive Cancer Center, Los Angeles, CA; Johns Hopkins University, Baltimore, MD; Roswell Park Cancer Institute, Buffalo, NY; Vanderbilt University School of Medicine, Nashville, TN; Cancer Institute of New Jersey, New Brunswick, NJ; University of Chicago and Northwestern University Medical School, Chicago, IL; and Eli Lilly and Company, Indianapolis, IN
Steven Nicol - From the Massachusetts General Hospital and Dana-Farber Cancer InstituteBoston, MA; University of Southern California–Norris Comprehensive Cancer Center, Los Angeles, CA; Johns Hopkins University, Baltimore, MD; Roswell Park Cancer Institute, Buffalo, NY; Vanderbilt University School of Medicine, Nashville, TN; Cancer Institute of New Jersey, New Brunswick, NJ; University of Chicago and Northwestern University Medical School, Chicago, IL; and Eli Lilly and Company, Indianapolis, IN
William Oh - From the Massachusetts General Hospital and Dana-Farber Cancer InstituteBoston, MA; University of Southern California–Norris Comprehensive Cancer Center, Los Angeles, CA; Johns Hopkins University, Baltimore, MD; Roswell Park Cancer Institute, Buffalo, NY; Vanderbilt University School of Medicine, Nashville, TN; Cancer Institute of New Jersey, New Brunswick, NJ; University of Chicago and Northwestern University Medical School, Chicago, IL; and Eli Lilly and Company, Indianapolis, IN
Walter Stadler - From the Massachusetts General Hospital and Dana-Farber Cancer InstituteBoston, MA; University of Southern California–Norris Comprehensive Cancer Center, Los Angeles, CA; Johns Hopkins University, Baltimore, MD; Roswell Park Cancer Institute, Buffalo, NY; Vanderbilt University School of Medicine, Nashville, TN; Cancer Institute of New Jersey, New Brunswick, NJ; University of Chicago and Northwestern University Medical School, Chicago, IL; and Eli Lilly and Company, Indianapolis, IN
Publication Details: Journal of clinical oncology, Vol.18(9), pp.1921-1927
Date published: 05/09/2000
Academic Unit: Lung Cancer/Thoracic Oncology Program
Language: English
Resource Type: Journal article
Identifiers: 991031654835404646